Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms

The treatment for anaplastic lymphoma kinase (ALK)‐positive lung cancer has been rapidly evolving since the introduction of several ALK tyrosine kinase inhibitors (ALK‐TKI) in clinical practice. However, the acquired resistance to these drugs has become an important issue. In this study, we collecte...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Yanagitani, Noriko, Uchibori, Ken, Koike, Sumie, Tsukahara, Mika, Kitazono, Satoru, Yoshizawa, Takahiro, Horiike, Atsushi, Ohyanagi, Fumiyoshi, Tambo, Yuichi, Nishikawa, Shingo, Fujita, Naoya, Katayama, Ryohei, Nishio, Makoto
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7060465/
https://ncbi.nlm.nih.gov/pubmed/31961053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14314
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars